Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
Rongrong Zou, Ling Peng, Dan Shu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1681-1693
Open Access | Times Cited: 223
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 683-695
Open Access | Times Cited: 45
Clinical course and management of COVID-19 in the era of widespread population immunity
Eric A. Meyerowitz, Jake Scott, Aaron Richterman, et al.
Nature Reviews Microbiology (2023) Vol. 22, Iss. 2, pp. 75-88
Closed Access | Times Cited: 36
Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
Divya Teli, Pankti C. Balar, Kishan Patel, et al.
Metabolites (2023) Vol. 13, Iss. 2, pp. 309-309
Open Access | Times Cited: 29
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
Xiaohong Fan, Xiahong Dai, Yun Ling, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 2, pp. 129-139
Closed Access | Times Cited: 27
Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Fangyuan Tian, Qiyi Feng, Zhaoyan Chen
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 2, pp. 106870-106870
Open Access | Times Cited: 23
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
Jakob J Malin, Stephanie Weibel, Henning Gruell, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 7, pp. 1586-1598
Open Access | Times Cited: 19
Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials
Ya Gao, Ming Liu, Zhifan Li, et al.
Clinical Microbiology and Infection (2023) Vol. 29, Iss. 8, pp. 979-999
Open Access | Times Cited: 17
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
Meital Zur, Thalia Peselev, Stav Yanko, et al.
Antiviral Research (2023) Vol. 221, pp. 105768-105768
Closed Access | Times Cited: 15
A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19
Surojit Banerjee, Debadri Banerjee, Anupama Singh, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 332-332
Open Access | Times Cited: 13
Clinical efficacy and safety of molnupiravir for nonhospitalized and hospitalized patients with COVID‐19: A systematic review and meta‐analysis of randomized control trials
Po‐Yu Huang, Tinghui Liu, Jheng‐Yan Wu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 3
Closed Access | Times Cited: 13
Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
Karima Benaicha, Raja Ram Khenhrani, Maha Veer, et al.
Cureus (2023)
Open Access | Times Cited: 13
Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis
Behnam Amani, Bahman Amani
Reviews in Medical Virology (2024) Vol. 34, Iss. 4
Closed Access | Times Cited: 5
Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices
Karolina Akinosoglou, Georgios Schinas, Emmanouil-Angelos Rigopoulos, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 787-787
Open Access | Times Cited: 11
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients
Mingyao Sun, Honghao Lai, Jiajie Huang, et al.
Journal of Antimicrobial Chemotherapy (2023) Vol. 78, Iss. 9, pp. 2131-2139
Closed Access | Times Cited: 11
Mathematical analysis of the COVID-19 pandemic dynamics in the emergence of resistant strains of SARS-CoV-2 in a vaccinated and non-vaccinated population: a real-world scenario in most countries
Ugo Avila-Ponce de León, Ángel Pérez, Eric Ávila-Vales
Elsevier eBooks (2025), pp. 63-80
Closed Access
Review: The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
Eric A. Meyerowitz, Yijia Li
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. 908-917
Open Access | Times Cited: 10
COMPUTATIONAL MULTI-FACTOR MODELING TO THE SIMULTANEOUS DETERMINATION OF ASSAY AND RELATED SUBSTANCES METHOD DEVELOPMENT, VALIDATION, AND IDENTIFICATION OF MAJOR DEGRADATION PRODUCT OF COVID-19 DRUG MOLNUPIRAVIR BY HPLC: A STRATEGIC RESEARCH USING AQBD
Sandip Kumar Dey, Sumanta Mondal
International Journal of Applied Pharmaceutics (2025), pp. 204-224
Open Access
Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan
Masahiro Kimata, Asuka Watanabe, Yukiko Yanagida, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 4, pp. 1119-1136
Open Access | Times Cited: 9
Clinical effectiveness of molnupiravir in patients with COVID-19 undergoing haemodialysis
Yi‐Chin Chang, Yi‐Chun Chen, Chiang-Chi Huang, et al.
International Journal of Antimicrobial Agents (2023) Vol. 62, Iss. 1, pp. 106834-106834
Open Access | Times Cited: 9
Molnupiravir: an antiviral drug against COVID-19
Bhavarth Dave, Kashvi C. Shah, Mehul R. Chorawala, et al.
Archives of Virology (2023) Vol. 168, Iss. 10
Closed Access | Times Cited: 8
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
Yankun Liang, Lin Ma, Yuting Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 7
Saline nasal irrigation and gargling in COVID-19: a multidisciplinary review of effects on viral load, mucosal dynamics, and patient outcomes
Suzy Huijghebaert, Shehzad Parviz, David Rabago, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top